Abstract:Objectives Metered-dose inhalers (MDIs) contain propellants which are potent greenhouse gases. Many agencies propose a switch to alternative, low global warming potential (GWP) inhalers, such as dry powder inhalers (DPIs). We aimed to analyse the impact on greenhouse gas emissions and drug costs of making this switch. Setting We studied National Health Service prescription data from England in 2017 and collated carbon footprint data on inhalers commonly used in England. Design Inhalers were separated into different categories according to their mechanisms of action (eg, short-acting beta-agonist). Within each category we identified low and high GWP inhalers and calculated the cost and carbon impact of changing to low GWP inhalers. We modelled scenarios for swapping proportionally according to the current market share of each equivalent DPI (model 1) and switching to the lowest cost pharmaceutically equivalent DPI (model 2). We also reviewed available data on the carbon footprint of inhalers from scientific publications, independently certified reports and patents to provide more accurate carbon footprint information on different types of inhalers. Results If MDIs using HFA propellant are replaced with the cheapest equivalent DPI, then for every 10% of MDIs changed to DPIs, drug costs decrease by £8.2M annually. However if the brands of DPIs stay the same as 2017 prescribing patterns, for every 10% of MDIs changed to DPIs, drug costs increase by £12.7M annually. Most potential savings are due to less expensive long-acting beta-agonist (LABA)/inhaled corticosteroids (ICS) inhalers. Some reliever inhalers (eg, Ventolin) have a carbon footprint over 25 kg CO 2 e per inhaler, while others use far less 1,1,1,2-tetrafluoroethane (HFA134a) (eg, Salamol) with a carbon footprint of <10 kg CO 2 e per inhaler. 1,1,1,2,3,3,3-Heptafluoropropane (HFA227ea) LABA/ICS inhalers (eg, Flutiform) have a carbon footprint over 36 kg CO 2 e, compared with an equivalent HFA134a combination inhaler (eg, Fostair) at <20 kg CO 2 e. For every 10% of MDIs changed to DPIs, 58 kt CO 2 e could be saved annually in England. Conclusions Switching to DPIs would result in large carbon savings and can be achieved alongside reduced drug costs by using less expensive brands. Substantial carbon savings can be made by using small volume HFA134a MDIs, in preference to large volume HFA134a MDIs, or those containing HFA227ea as a propellant.

Environmental impact of pressurised metered dose inhalers versus dry powder and soft mist inhalers at a tertiary Melbourne hospital

Environmentally sustainable opportunities for health systems: metered-dose inhaler prescribing, dispensing, usage, and waste at The Ottawa Hospital

The environmental impact of inhaled therapy: making informed treatment choices

The environmental burden of inhalation

Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England

Thoughtful prescription of inhaled medication has the potential to reduce inhaler-related greenhouse gas emissions by 85

Environmental impact of inhaled medicines: A Thoracic Society of Australia and New Zealand position statement

Impact of inhalers used in the treatment of respiratory diseases on global warming

Turning green: the impact of changing to more eco-friendly respiratory healthcare - a carbon and cost analysis of Dutch prescription data

Evaluating inhaler technique, patient preferences and opportunities for improvement in hospitals in the UK

[Reduction of greenhouse gas emissions by inhaler choice in the therapy of asthma and COPD patients]

Greenhouse gas reduction in anaesthesia practice: a departmental environmental strategy

Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study

In vitro evaluation of solution-based pressurised metered dose inhaler sprays with low GWP propellants

Effect of low climate impact vs. high climate impact inhalers for patients with asthma and COPD-a nationwide cohort analysis

Understanding the performance of pressurized metered dose inhalers formulated with low Global warming potential propellants

Comparison of the Ecological Footprints of administering Salbutamol by Metered-Dose Inhaler and by Nebulization in Emergency Treatment of Acute Asthma

The carbon footprint associated with the overuse of short-acting β2-agonists in asthma patients

Promoting behavioural change by educating anaesthetists about the environmental impact of inhalational anaesthetic agents: A systematic review

Reducing the environmental impact of asthma and its treatment: findings from the SENTINEL pilot site

The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis